problems with glp-1 drugs Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity The GLP-1 Agonists and Obesity:
Description
Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov
Formulated without dairy, soy, gluten, wheat, peanuts, tree nuts, eggs, fish, shellfish, artificial sweeteners, or preservatives
Semaglutide was removed in February 2025
New users of GLP-1RAs were matched based on age, demographics, comorbidities and medication use by using 1:1 propensity matching with other glucose-lowering drugs
